IGC Pharma, Inc. (IGC) Stock Score, Valuation & Financial Research
IGC Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 9/100.
Quick answer for IGC
IGC Pharma, Inc. currently has a Wall Street Score of 9/100. The stored market price is $0.27. Its financial score is 5/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What IGC Pharma, Inc. does
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC financial snapshot
- Wall Street Score:
- 9/100
- Current price:
- $0.27
- Market capitalization:
- $27.2M
- Revenue:
- $1.1M
- Net income:
- $-7.9M
- Free cash flow:
- $-6.1M
- Cash:
- $331K
- Total debt:
- $1.1M
- EPS:
- -0.08
- Financial score:
- 5/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-6.1M, showing cash burn in the current stored period.
- The balance sheet shows $331K of cash versus $1.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 5/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research IGC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.